Explore

Trendline Trendline
Alnylam Pharmaceuticals to Present Vutrisiran Data at Heart Failure 2026, Highlighting Efficacy in ATTR-CM

Alnylam Pharmaceuticals to Present Vutrisiran Data at Heart Failure 2026, Highlighting Efficacy in ATTR-CM

Alnylam Pharmaceuticals to Present Vutrisiran Data at Heart Failure 2026, Highlighting Efficacy in ATTR-CM
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease
Trendline Trendline
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data
Trendline Trendline
Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics
Trendline Trendline
GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe

GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe

GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Contineum Therapeutics Reports Positive Results from PIPE-791 Phase 1b Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Phase 1b Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Phase 1b Trial for Chronic Pain
Trendline Trendline
Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments
Trendline Trendline
Molecular Partners' MP0317 Shows Promise in Tumor-Localized CD40 Activation, Phase 2 Trial Initiated

Molecular Partners' MP0317 Shows Promise in Tumor-Localized CD40 Activation, Phase 2 Trial Initiated

Molecular Partners' MP0317 Shows Promise in Tumor-Localized CD40 Activation, Phase 2 Trial Initiated
Trendline Trendline
Contineum Therapeutics Reports Positive Results from PIPE-791 Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Trial for Chronic Pain
Trendline Trendline
FDA Advisory Committee Recommends Against AstraZeneca's Breast Cancer Drug Approval

FDA Advisory Committee Recommends Against AstraZeneca's Breast Cancer Drug Approval

FDA Advisory Committee Recommends Against AstraZeneca's Breast Cancer Drug Approval
Trendline Trendline
Corcept Therapeutics Reports Two-Year Survival Benefit in ALS Patients from Dazucorilant Phase 2 Study

Corcept Therapeutics Reports Two-Year Survival Benefit in ALS Patients from Dazucorilant Phase 2 Study

Corcept Therapeutics Reports Two-Year Survival Benefit in ALS Patients from Dazucorilant Phase 2 Study